NIAAA Medications Development Data Coordinating Center

药物疗法在治疗酒精依赖和酒精相关疾病方面很有希望，并为更广泛的酒精依赖个体提供更多的治疗选择。NIAAA的一个主要优先事项是促进发现、开发和提供治疗酒精使用障碍和酒精相关医学障碍的药物。为了加速药物开发过程中的先导化合物，NIAAA已经建立了一个二期临床试验项目，NIAAA临床研究小组（NCIG），以证明药物的初步有效性。该合同的目的是为NCIG建立一个数据协调中心，以开展使用新型候选药物治疗酒精使用障碍的多中心临床试验的各个方面。

Pharamacotherapy holds much promise for treating alcohol dependence and alcohol-related disorders, and for offering more treatment options to a wider spectrum of alcohol dependent individuals. A major priority of NIAAA is to facilitate the discovery, development, and delivery of medications to treat alcohol use disorders and alcohol-related medical disorders. To accelerate lead compounds in the drug development process, NIAAA has established a Phase 2 clinical trials program, the NIAAA Clinical Investigations Group (NCIG), to demonstrate the preliminary effectiveness of medications. The purpose of this contract is to establish a Data Coordinating Center for the NCIG to conduct all aspects of multi-center clinical trials for the treatment of alcohol use disorders using novel drug candidates.